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No Increased Risk of Cancer after Coal Tar Treatment
in Patients with Psoriasis or Eczema
Judith H.J. Roelofzen1,2, Katja K.H. Aben1,3, Ursula T.H. Oldenhof1, Pieter-Jan Coenraads4,
Hans A. Alkemade5, Peter C.M. van de Kerkhof2, Pieter G.M. van der Valk2 and Lambertus A.L.M. Kiemeney1,3,6
Coal tar is an effective treatment for psoriasis and eczema, but it contains several carcinogenic compounds.
Occupational and animal studies have shown an increased risk of cancer after exposure to coal tar. Many
dermatologists have abandoned this treatment for safety reasons, although the risk of cancer after coal tar in
dermatological practice is unclear. This large cohort study included 13,200 patients with psoriasis and eczema.
Information on skin disease and treatment, risk factors, and cancer occurrence was retrieved from medical files,
questionnaires, and medical registries. Proportional hazards regression was used to evaluate differences in
cancer risk by treatment modality. Patients treated with coal tar were compared with a reference category of
patients treated with dermatocorticosteroids (assumed to carry no increased cancer risk). The median exposure
to coal tar ointments was 6 months (range 1–300 months). Coal tar did not increase the risk of non-skin
malignancies (hazard ratio (HR) 0.92; 95% confidence interval (CI) 0.78–1.09), or the risk of skin cancer (HR 1.09;
95% CI 0.69–1.72). This study has sufficient power to show that coal tar treatment is not associated with
an increased risk of cancer. These results indicate that coal tar can be maintained as a safe treatment in
dermatological practice.
Journal of Investigative Dermatology (2010) 130, 953–961; doi:10.1038/jid.2009.389; published online 17 December 2009
INTRODUCTION
Coal tar is one of the oldest topical treatments in dermatol-
ogy. It is well established in the management of various
skin diseases, especially psoriasis and eczema. Coal tar is a
complex mixture of more than 10,000 compounds, including
high concentrations of polycyclic aromatic hydrocarbons
(PAHs). Coal tar is obtained by heating coal in the absence of
air. Medical pix lithantracis is produced by mixing two-thirds
of pitch of high-temperature sources with one-third of tar oils.
Liquor carbonis detergens is obtained by extraction of 20 g
pix lithantracis with 100ml alcohol and addition of 5 g
polysorbate. In general, the use of pix lithantracis is restricted
to a hospital or day-care setting because of staining of
furniture and clothes and the strong odor, but liquor carbonis
detergens can be used at home. It is well known that some
PAHs, such as benzo(a)pyrene and benz(a)antracene, are
carcinogenic (Bickers 1981; Boffetta et al., 1997). Animal
studies (IARC, 1985; Boffetta et al., 1997; Marston et al.,
2001) and occupational studies (IARC, 1985; Partanen and
Boffetta, 1994; Donato et al., 2000; Tsai et al., 2001) showed
increased risks of lung and non-melanoma skin cancer after
chronic exposure to coal tar. The risk of cancer after coal tar
treatment in dermatological practice is still unclear because
of the lack of large-scale observational studies. All studies
performed so far lacked sufficient numbers of patients,
follow-up data, or data on potential risk factors, e.g.,
treatment, smoking, and sun exposure, to accurately estimate
the risk of cancer after coal tar application (Maughan et al.,
1980; Stern et al., 1980; Pittelkow et al., 1981; Larko and
Swanbeck, 1982; Jones et al., 1985; Hannuksela-Svahn et al.,
2000). Despite the lack of clear evidence of an increased risk
of cancer after dermatological use of coal tar, many
dermatologists around the world have abandoned coal tar
as a therapeutic option (Roelofzen et al., 2007; Paghdal and
Schwartz, 2009). Some dermatologists even consider the use
of coal tar obsolete (Mrowietz and Rott, 2007). However,
several alternative therapies for psoriasis and eczema, such as
psoralen plus ultraviolet light A (PUVA) and ultraviolet B, are
known or suspected carcinogens as well, and therapies such
as cyclosporine, methotrexate, and topical calcineurin
inhibitors may facilitate carcinogenesis by its immunosup-
pressive action. We therefore question whether it is justified
to abandon coal tar before making a valid assessment of the
risk of cancer. To assess the risk of cancer after coal tar
treatment in patients with psoriasis or eczema, we initiated a
large historical cohort study: the LAte effects of coal
Tar treatment in Eczema and psoriasis; the Radboud
study (LATER study).
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RESULTS
Characteristics of the cohort
In Table 1, 809 patients in the total cohort of 14,009 patients
were excluded from the analyses because of missing or
invalid data on key variables, such as diagnosis of psoriasis or
eczema or date of diagnosis. One-third of the cohort
consisted of patients with psoriasis and two-thirds with
eczema. Over 60% of the patients with psoriasis had a
severe form, i.e., 410% of their body was affected. In
eczema, this applied to o50%. In the total cohort, 61% of
the patients had been treated with coal tar: approximately
60% with liquor carbonis detergens and 40% with pix
lithantracis. Many other therapies had also been applied to
these patients. Systemic therapies and photo(chemo)therapy
had been applied to 25 and 46% of the patients with
psoriasis, respectively. These percentages were much lower
in the patients with eczema.
Valid information on duration of coal tar therapy could be
obtained from approximately 1,100 patients only. This made
a robust dose–response evaluation of coal tar exposure and
the risk of cancer impossible. The available information
showed a median use of pix lithantracis for 4 months (range
1–300 months) and of liquor carbonis detergens for 6 months
(range 1–500 months).
Risk of cancer after coal tar treatment
The median duration of follow-up was 21 years. During
follow-up, 1,327 tumors had been diagnosed (Table 2).
Table 3 presents the results of the multivariable proportional
hazards regression analyses on the relative risk of cancer after
coal tar treatment. No increased risk of skin cancer and non-
skin cancer was found after coal tar treatment (hazard ratio
(HR) 1.09 and 95% confidence interval (CI) 0.69–1.72; and
HR 0.92 and 95% CI 0.78–1.09, respectively). The risk of
hematological malignancies seemed to be slightly decreased,
especially in psoriasis, but these analyses only included a
small number of tumors. In patients with eczema, the risk of
gastrointestinal cancer after coal tar treatment was approxi-
mately 50% lower than in patients treated with dermatocor-
ticosteroids alone (HR 0.57; 95% CI 0.37–0.89). Opposite
results were observed regarding the risk of bladder and
urinary tract cancer in patients with eczema (HR 1.83; 95%
CI 0.73–4.58) when compared with patients with psoriasis
(HR 0.51; 95% CI 0.14–1.92). However, these results were
based on small numbers (30 and 21, respectively) and were
not statistically significant.
Table 4 presents the results of the multivariable analyses
on the high (pix lithantracis) and low (liquor carbonis
detergens) coal tar exposure categories. Neither of the coal
tar categories showed an increased risk of non-skin cancer.
The HR of skin cancer for pix lithantracis in patients with
psoriasis or eczema was 0.66 (95% CI 0.33–1.30), whereas it
was 1.28 (95% CI 0.80–2.06) for liquor carbonis detergens.
Comparable results were found in the psoriasis group: HRs
for liquor carbonis detergens and pix lithantracis were 1.35
(95% CI 0.53–3.44) and 0.33 (95% CI 0.07–1.69), respec-
tively. Similar risk estimates of gastrointestinal cancer were
observed in patients with psoriasis and eczema in both the
low- and high-exposure groups. In patients with eczema, the
risk of gastrointestinal cancer after liquor carbonis detergens
was almost 50% lower when compared with the reference
group (HR 0.54; 95% CI 0.33–0.89). In patients with psoriasis
or eczema, the risk of cancer of the female reproductive
organs after pix lithantracis was increased (HR 1.26; 95% CI
0.61–2.58). This was caused by a 3-fold increased risk of
tumors of the female reproductive organs in patients with
eczema (HR 2.90; 95% CI 1.31–6.43).
DISCUSSION
The main conclusion of this study is that, overall, the use of
coal tar ointments is not associated with an increased risk of
cancer. With regard to the risk of skin cancer after coal tar
exposure, separate analyses of pix lithantracis and liquor
carbonis detergens showed unexpected results: a higher risk
of skin cancer in the ‘‘low’’ coal tar exposure group than in
the ‘‘high’’ exposure group (HR 1.28 vs HR 0.66). However,
these results were not statistically significant. The intensity of
PAH exposure is not only determined by the PAH concentra-
tion, but also by the duration of exposure. The use of pix
lithantracis is restricted to a hospital or day-care setting
because of staining of furniture and clothes and the strong
odor. In contrast, liquor carbonis detergens can be used at
home and therefore, most patients use these ointments for a
longer period of time. Patients treated with pix lithantracis
were probably exposed to a high concentration of PAHs over
a short period, whereas patients treated with liquor carbonis
detergens were exposed to a lower dose of PAHs over a
longer period. Occupational studies have shown that the risk
of non-melanoma skin cancer was increased after chronic
exposure to low doses of PAHs (IARC, 1985; Partanen and
Boffetta, 1994; Donato et al., 2000; Tsai et al., 2001).
Therefore, it seems possible that tissue (skin) is capable of
repairing any damage after short-term exposure to PAHs, but
may not always be capable of doing so during long-term
exposure.
Most of the studies that analyzed the risk of skin cancer
after coal tar treatment did not find an increased risk of non-
melanoma skin cancer (Maughan et al., 1980; Pittelkow
et al., 1981; Larko and Swanbeck, 1982; Jones et al., 1985;
Hannuksela-Svahn et al., 2000). Only Stern et al., (1980)
reported an increased risk of non-melanoma skin cancer in
patients with psoriasis. However, these patients were drawn
from the PUVA cohort and all had therefore received this
carcinogenic therapy.
Very few studies have analyzed the risk of internal
malignancies after coal tar treatment. A fairly small study
by Jones et al. (1985) evaluated the risk of internal
malignancies in 719 patients with psoriasis. These patients
had received coal tar therapy intermittently over a 10-year
period and had never been exposed to ultraviolet B, PUVA,
or cytotoxic therapies. The results indicated that coal tar
treatment did not increase the risk of internal tumors.
Hannuksela-Svahn et al. (2000) conducted a large cohort
study to estimate the risk of cancer in 5,687 hospitalized
patients with psoriasis. A nested case–control study within
this cohort study showed a nonsignificant increase in the risk
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Table 1. Characteristics of patients in the total cohort and stratified by psoriasis and eczema
Characteristic Total cohort (13,200) Psoriasis (4,315) Eczema (8,885)
Gender (male/female, %) 47/53 52/48 45/55
Median age at diagnosis (range) 28.4 years (0–95.7) 31.1 years (0–95.7) 27.2 years (0–91.4)
Calendar period of diagnosis
1960–1969 (%) 2,476 (18.8) 931 (21.6) 1,545 (17.4)
1970–1979 (%) 4,160 (31.5) 1,575 (36.5) 2,585 (29.1)
1980–1989 (%) 6,564 (49.7) 1,809 (41.9) 4,755 (53.3)
Status at end of follow-up
Diagnosed with cancer (%) 1,048 (7.9) 421 (9.8) 627 (7.1)
Deceased without cancer (%) 1,951 (14.8) 725 (16.8) 1,226 (13.8)
Censured at 31 December 2003 (%) 9,346 (70.8) 2,840 (65.8) 6,506 (73.2)
Lost to follow-up (%) 855 (6.5) 329 (7.6) 526 (5.9)
Median duration of follow-up (years) 21 22.5 20.5
1–9 years (%) 1,433 (10.9) 502 (11.6) 928 (10.5)
10–19 years (%) 4,634 (35.1) 1,219 (28.3) 3,414 (38.4)
20–29 years (%) 4,415 (33.4) 1,528 (35.4) 2,856 (32.5)
430 years (%) 2,718 (20.6) 1,063 (24.6) 1,654 (18.6)
Severity of skin disease (% area affected)
o1% 2,759 (20.9) 375 (8.7) 2,381 (26.8)
2–9% 4,528 (34.3) 1,290 (29.9) 3,234 (36.4)
10–30% 3,907 (29.6) 1,696 (39.3) 2,221 (25.0)
430% 2,006 (15.2) 954 (22.1) 1,049 (11.8)
Use of coal tar ointments (%)
Never1 5,138 (38.9) 1,234 (28.6) 3,904 (43.9)
Only liquor carbonis detergens, no pix lithantracis1 4,927 (37.3) 2,256 (52.3) 2,671 (30.1)
Pix lithantracis with/without liquor carbonis detergens1 3,135 (23.8) 825 (19.1) 2,310 (26.0)
Use of other therapies (%)
Topical
Local corticosteroids 96.6 96.6 96.5
Vitamin D3 analogs 11.5 32.4 —
Topical calcineur inhibitors 1.9 1.0 2.4
Dithranol 3.4 10.2 —
Systemic
Methotrexate 5.2 14.9 0.5
Retinoids 4.9 13.2 —
Cyclosporin 1.7 3.5 0.8
Fumarates 1.8 5.1 —
Oral prednisone 9.6 5.1 11.8
Table 1 continued on the following page
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of non-Hodgkin’s lymphoma after treatment with the Goeck-
erman regimen (odds ratio 1.2; 95% CI 0.1–16.8).
In the tumor-specific analyses, we found a decreased risk
of gastrointestinal cancer. This decreased risk seemed to be
driven by a decreased risk of colon cancer (HR 0.57; 95% CI
0.32–1.03). Although we did not expect the gastrointestinal
tract to be a tumor risk site after coal tar treatment (in contrast
with the bladder, lymphatic, and hematological system), a
decreased risk was unexpected and we cannot think of a
logical explanation. The study by Jones et al. (1985) reported
an increased risk of colon cancer in men, but not in women.
However, these results were based on very small numbers of
tumors (n¼ 6).
Another remarkable finding in our study was the difference
in the risk of bladder and urinary tract cancer between
patients with psoriasis (HR 0.51; 95% CI 0.14–1.92) and with
eczema (HR 1.83; 95% CI 0.73–4.58). However, the numbers
of tumors were fairly small and therefore this finding may be
due to chance.
This is the first cohort study with sufficient numbers of
patients and follow-up for assessing the overall risk of cancer
after limited coal tar treatment in a valid way. In addition,
data on the possible risk factors for cancer, such as age,
smoking, and non-coal tar therapies, were collected that
made it possible to adjust all estimates for these risk factors.
Unfortunately, we were unable to estimate a dose–
response relation of coal tar exposure and the risk of cancer.
It was impossible to derive reliable information on the exact
duration of coal tar treatment from the medical files. Only a
limited proportion of the patients (treated with coal tar)
returned the questionnaire and answered the questions on the
duration of coal tar therapy (approximately 1,100 patients).
The number of cases was therefore too small to reliable
estimate the risk of cancer after different levels of coal tar
Table 1. Continued
Characteristic Total cohort (13,200) Psoriasis (4,315) Eczema (8,885)
Photo(chemo)therapy
PUVA 13.1 27.2 6.2
UVB 16.7 33.5 8.6
Goeckerman 3.5 9 0.9
Smoking status (%)2
Never 1,499 (11.4) 400 (9.3) 1,099 (12.4)
Former 2,489 (18.9) 997 (23.1) 1,492 (16.8)
Current 1,526 (11.5) 559 (13.0) 967 (10.7)
Unknown 16 (0.1) 6 (0.1) 10 (0.1)
Missing (no data from questionnaire) 7,670 (58.1) 2,353 (54.5) 5,317 (59.8)
Alcohol (%)2
o1 Days/week 2,561 (19.4) 859 (19.9) 1,702 (19.2)
1–2 Days/week 1,062 (8.0) 383 (8.9) 679 (7.6)
3–5 Days/week 824 (6.3) 296 (6.9) 528 (5.9)
45 Days/week 973 (7.4) 373 (8.6) 600 (6.8)
Unknown 110 (0.8) 51 (1.2) 59 (0.7)
Missing (no data from questionnaire) 7,670 (58.1) 2,353 (54.5) 5,317 (59.8)
Skin type (%)2
Type 1 (always burns, never tans) 426 (3.3) 167 (3.9) 259 (2.9)
Type 2 (burns easily, tans minimally) 1,764 (13.3) 555 (12.9) 1,209 (13.6)
Type 3 (burns moderately, tans to light brown 2,688 (20.4) 977 (22.6) 1,711 (19.3)
Type 4 (burns minimally, tans well) 564 (4.3) 226 (5.2) 338 (3.8)
Unknown 88 (0.6) 37 (0.9) 51 (0.6)
Missing (no data from questionnaire) 7,670 (58.1) 2,353 (54.5) 5,317 (59.8)
Abbreviations: PUVA, psoralen plus UVA.
1Patients in all three categories could also have been treated with other therapies.
2Percentages are based on the part of the cohort that returned the questionnaire (5,530, 1,962, and 3,568 in the total cohort and in patients with psoriasis and
with eczema, respectively).
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exposure. The information on duration of exposure showed
that patients were treated with coal tar for a relatively
short period of time. This is consistent with our experience
from daily practice in which pix lithantracis is mainly used
during hospitalization or in day-care clinic. The duration of
treatment with liquor carbonis detergens is somewhat longer,
but still limited and frequently alternated with other topical
therapies. We therefore believe that our data reflect the
duration of coal tar use in dermatological practice.
No distinction could be made between the risk of
melanoma and squamous cell skin carcinoma, because
we did not make this subdivision in the questionnaire.
Although we received type-specific cancer incidence data
from the Netherlands Cancer Registry (NCR; and Statistics
Netherlands), we could not make this subdivision of skin
cancer in our final analyses because we also used data on
cancer occurrence from the questionnaires. Basal cell
carcinomas are not registered in the NCR. Consequently,
Table 2. Observed number of tumors in the total cohort and stratified by psoriasis and eczema and by exposure to
coal tar
Total cohort (13,200) Psoriasis (4,315) Eczema (8,885) Coal tar (8,062) No coal tar (5,138)
Tumor site n (%) n (%) n (%) n (%) n (%)
Overall cancer 1,327 (10.1) 512 (11.9) 815 (9.2) 794 (9.9) 533 (10.4)
Skin cancer1 163 (1.2) 83 (1.9) 80 (0.9) 109 (1.4) 54 (1.1)
Internal malignancies 1,192 (9.0) 444 (10.3) 748 (8.4) 707 (8.8) 485 (9.4)
Specific tumor groups
Hematological 52 (0.4) 18 (0.4) 34 (0.4) 32 (0.4) 20 (0.4)
Lymphoma 53 (0.4) 21 (0.5) 32 (0.4) 30 (0.4) 23 (0.5)
Lung 233 (1.8) 83 (1.9) 150 (1.7) 147 (1.8) 86 (1.7)
Gastrointestinal 218 (1.7) 81 (1.9) 137 (1.5) 114 (1.4) 104 (2.0)
Bladder and urinary tract 58 (0.4) 25 (0.6) 33 (0.4) 35 (0.4) 23 (0.5)
Breast 171 (1.3) 61 (1.4) 110 (1.2) 101 (1.3) 70 (1.4)
Female reproductive organs 113 (0.9) 39 (0.9) 74 (0.8) 79 (1.0) 34 (0.7)
Prostate 108 (0.8) 46 (1.1) 62 (0.7) 62 (0.8) 46 (0.9)
1Excluding basal cell carcinoma.
Table 3. Hazard ratios (95% confidence intervals) for patients with psoriasis or eczema treated with coal tar and
stratified by skin disease
Psoriasis or eczema Psoriasis Eczema
Tumor Cases HR (95% CI)1 Cases HR (95% CI)1 Cases HR (95% CI)1
Overall cancer 1,180 0.92 (0.79–1.08) 441 0.79 (0.57–1.09) 739 0.96 (0.80–1.15)
Skin2 145 1.09 (0.69–1.72) 71 1.08 (0.43–2.72) 74 1.06 (0.62–1.83)
Internal malignancies 1,061 0.92 (0.78–1.09) 383 0.78 (0.55–1.10) 678 0.97 (0.80–1.17)
Specific tumor groups
Hematological malignancies 48 0.80 (0.38–1.72) 16 0.56 (0.09–3.44) 32 0.95 (0.41–2.19)
Breast 147 1.00 (0.66–1.53) 53 1.03 (0.43–2.50) 94 0.95 (0.57–1.57)
Lung 207 1.22 (0.82–1.83) 71 0.97 (0.38–2.46) 136 1.29 (0.75–2.23)
Gastrointestinal 203 0.64 (0.45–0.92) 73 0.72 (0.36–1.44) 130 0.57 (0.37–0.89)
Bladder and urinary tract 51 1.33 (0.63–2.81) 21 0.51 (0.14–1.92) 30 1.83 (0.73–4.58)
Prostate 96 0.85 (0.46–1.55) 40 0.84 (0.26–2.70) 56 0.75 (0.36–1.59)
Female reproductive organs 101 1.59 (0.85–2.81) 32 0.57 (0.13–2.40) 69 2.03 (0.99–4.14)
Abbreviations: CI, confidence interval; HR, hazard ratio.
1All HRs were adjusted for age, gender, severity of skin disease, calendar period, use of psoralen plus UVA, use of systemic therapy, and smoking.
2Excluding basal cell carcinoma.
Patients treated with coal tar (n¼ 8,062) were compared with the reference group (n¼ 3,705 patients treated with dermatocorticosteroids alone).
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we could not include this type of skin cancer in our analyses.
Occupational studies on PAH exposure showed an increased
risk of squamous cell carcinomas, and hence this type of skin
cancer may be more related to PAH exposure than basal cell
carcinoma (IARC, 1985; Partanen and Boffetta, 1994; Boffetta
et al., 1997; Donato et al., 2000; Marston et al., 2001; Tsai
et al., 2001).
Besides coal tar, many other therapies have been applied
in the treatment of psoriasis and eczema. Most of these
therapies have mild-to-moderate or even severe side effects.
The use of topical calcineurin inhibitors in eczema has
been increasing since their introduction. These agents modify
the immune regulatory functions of the skin and may there-
fore increase the risk of skin cancer (Enderlein et al., 2005;
Ring et al., 2005). Until now, epidemiological studies have
not shown any increased risk of (skin) cancer after the use
of calcineurin inhibitors, and only short-term follow-up data
are available (Ring et al., 2005). If patients have severe skin
diseases or do not respond to topical treatment, systemic
therapies or photo(chemo)therapies can be applied. Most
of these modalities have moderate-to-severe carcinogenic
(PUVA and cyclosporine), hepatotoxic (methotrexate, reti-
noids), or teratogenic (retinoids) side effects (Greaves and
Weinstein, 1995; Lebwohl, 2003; Menter and Griffiths,
2007).
The risk of skin cancer after PUVA has been extensively
studied and most studies showed an increased risk of skin
cancer (Stern et al., 1998; Lindelof et al., 1999; Hannuksela-
Svahn et al., 2000; Nijsten and Stern, 2003). Several studies
showed that patients exposed to long-term treatment with
cyclosporine after an organ transplant have a significantly
increased risk of non-melanoma skin cancer (London et al.,
1995; Jensen et al., 1999; Lindelof et al., 2000; Ramsay et al.,
2000; Moloney et al., 2006). Some of the studies that
analyzed the risk of skin cancer after cyclosporine in psoriasis
also showed an increased risk of skin cancer (Arellano, 1997;
Marcil and Stern, 2001; Paul et al., 2003). Since their
introduction a few years ago, the use of biologicals (e.g.,
infliximab, etanercept, and adalimumab) has been rapidly
increasing in the treatment of psoriasis. These biologicals
suppress specific parts of the immune system, and hence in
theory, they may come along with an increased risk of
cancer. Cost-effectiveness and cost–utility studies comparing
traditional and new modalities are not yet available (Berger
and Gottlieb, 2007; Menter et al., 2008).
This large study with long time follow-up showed no
increased risk of cancer after coal tar therapy in patients
with psoriasis or eczema. Coal tar exposure was rather short
in our cohort, but this may reflect dermatological coal
tar exposure in practice. We conclude that our study showed
no reasons for safety concerns with respect to the risk
of cancer after the use of coal tar in patients with psori-
asis and eczema. It is therefore ungrounded to consider
coal tar as obsolete because of its alleged carcinogenic
action.
SUBJECTS AND METHODS
The LATER study was initiated in 2003. The cohort comprised
patients diagnosed with psoriasis or eczema between 1960 and 1990
in one of three large hospitals in the Netherlands. These hospitals
include two university hospitals and one teaching hospital. Between
January 2004 and June 2006, over 300,000 medical records stored in
the paper archives of the Departments of Dermatology at these
hospitals were searched manually to identify eligible patients. A
detailed description of data collection is described below. This study
was approved by the institutional review boards of all three hospitals
Table 4. Hazard ratios (95% confidence intervals) of cancer after use of LCD and PL in patients with psoriasis or
eczema and stratified by skin disease














Overall cancer 1,180 0.95 (0.80–1.12) 0.87 (0.70–1.09) 441 0.85 (0.60–1.19) 0.64 (0.40–1.03) 739 0.96 (0.78–1.17) 0.96 (0.74–1.23)
Skin2 145 1.28 (0.80–2.06) 0.66 (0.33–1.30) 71 1.35 (0.53–3.44) 0.33 (0.07–1.69) 74 1.13 (0.63–2.03) 0.83 (0.39–1.80)
Internal malignancies 1,061 0.93 (0.78–1.12) 0.91 (0.72–1.15) 383 0.81 (0.57–1.16) 0.70 (0.43–1.14) 678 0.96 (0.78–1.19) 0.98 (0.75–1.27)
Specific tumor groups
Hematological malignancies 48 0.84 (0.37–1.89) 0.74 (0.24–2.31) 16 0.49 (0.07–3.56) 0.87 (0.07–10.14) 32 1.06 (0.43–2.59) 0.73 (0.20–2.65)
Breast 147 1.00 (0.63–1.59) 1.02 (0.58–1.79) 53 0.97 (0.39–2.46) 1.18 (0.38–3.68) 94 0.97 (0.56–1.69) 0.91 (0.47–1.77)
Lung 207 1.30 (0.86–1.98) 1.06 (0.61–1.84) 71 1.10 (0.42–2.84) 0.68 (0.20–2.36) 136 1.43 (0.89–2.32) 1.20 (0.65–2.25)
Gastrointestinal 203 0.62 (0.42–0.93) 0.72 (0.40–1.28) 73 0.70 (0.33–1.44) 0.81 (0.30–2.20) 130 0.54 (0.33–0.89) 0.60 (0.32–1.11)
Bladder/urinary tract 51 1.23 (0.55–2.79) 1.61 (0.63–4.13) 21 0.47 (0.11–1.95) 0.61 (0.10–3.93) 30 1.72 (0.63–4.70) 2.22 (0.73–6.81)
Prostate 96 0.98 (0.51–1.87) 0.58 (0.22–1.50) 40 1.09 (0.33–3.54) 0.23 (0.02–2.14) 56 0.75 (0.33–1.74) 0.73 (0.26–2.07)
Female genital organs 101 1.26 (0.61–2.58) 2.28 (1.10–4.73) 32 0.63 (0.14–2.82) 0.43 (0.04–4.23) 69 1.51 (0.67–3.44) 2.89 (1.30–6.43)
Abbreviations: CI, confidence interval; HR, hazard ratio; LCD, liquor carbonis detergens; PL, pix lithantracis.
1All HRs were adjusted for age, gender, severity of skin disease, calendar period, use of psoralen plus UVA, use of systemic therapy, and smoking.
2Excluding basal cell carcinoma.
Patients treated with LCD (n¼4,927) and patients treated with PL (n¼3,135) (with or without LCD) were compared with the reference group
(n¼ 3,705 patients treated with dermatocorticosteroids alone).
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(Radboud University Nijmegen Medical Centre, Canisius-Wilhelmi-
na Ziekenhuis, and University Medical Centre Groningen).
Selection of patients and data collection from medical files
All patients included in this study had to be diagnosed with
psoriasis or eczema. Furthermore, patients had to fulfill the
following eligibility criteria: (1) the date of diagnosis of
psoriasis or eczema should be between 1960 and 1990 to
obtain sufficient follow-up for cancer to occur; and (2) the
patients had to have visited a dermatologist at least thrice, to
support the presumption that the skin disease was sufficiently
severe to require medical treatment. A total of 14,009
patients met the eligibility criteria. Administrative data were
recorded in a database. In addition, detailed information on
the medical history was collected from the medical files.
Data on variables collected from the medical files were
complete and of good quality for the majority of the variables.
Information on therapies that patients received was available
from the medical files. However, it was not possible to extract
information on the duration of the received therapies.
Medical history and data on cancer occurrence during
follow-up, especially non-skin cancer, were not always
recorded in the medical files. This information was supple-
mented by questionnaires and linkages to the NCR and
Causes of Death Registry. Recent data on vital status were
frequently unavailable in the medical files. This was
supplemented by linkages with the Hospital Information
Systems of the participating hospitals, the nationwide Dutch
Municipal Personal Records Database, and the Central
Bureau of Genealogy (described below).
Updating information
Figure 1 shows labor-intensive stepwise procedure that was
followed to update information on the place of residence and
vital status. At the time of inclusion, most administrative data
derived from the medical files were outdated, because many
patients had not visited their dermatologists recently. This
procedure included record linkages to the digital information
systems of the participating hospitals, an electronic telephone
record database, and the Municipal Personal Record Data-
base. In addition, municipalities and the Central Bureau of
Genealogy were consulted. By the end of these procedures,
the addresses and vital status of 88% of the patients were
updated (12,272/14,009). A total of 2,656 patients (19%) had
deceased and 229 patients had emigrated. In case a patient
had deceased, efforts were made to retrieve current informa-
tion of the partner, whom we considered as a potential proxy.
This resulted in the identification of 604 partners of deceased
patients (23.3%), but only 412 (68%) were still alive and
could be invited for the study.
Data collection through questionnaires
All patients with verified contact information (n¼9,387) and
412 partners of the deceased patients were invited to
participate in the study. They were sent an invitation letter,
an information leaflet, and a questionnaire. All subjects were
14,009 Patients identified
11,820 (84.3%) Updated 2,189 (15.6%) Not updated
99 Emigrations
1,253 Died
9,048 (64.5%) Not updated
3,984 (28.5%) Not found
2,922 Found (73.3%) 1,062 Not found (26.7%)






909 Not found (51.7%)
20 Emigrated
Linkage to hospital information system*
Linkage to computerized telephone records*









* Update to obtain patient’s most recent
  address before linkage to MPRD 
4,961 (35.5%) Updated
10,025 (71.5%) Found
Figure 1. Process of updating personal data and vital status of patients in the cohort. CBG, Central Bureau of Genealogy; MPRD, municipal personal records
database.
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asked for informed consent for participation in the study and
for linkage of their personal data to medical registers. They
were asked to fill out a detailed questionnaire concerning
demographic factors, use of alcohol (yes vs no and number of
glasses per day in past year), smoking habits (current/former/
never, and pack years), skin type, history of sunlight exposure
(use of tanning beds (never, 1–4, 5–10, 11–20, 21–50, or450
times per year) and residence in tropical areas (never, o1,
1–2, 3–5, or 6–10 years)), occupational history (including
history of outside occupation), detailed information on the
skin disease, and history of other (skin) diseases and cancer.
Questionnaires were scanned, processed, and data were
stored in a database (Teleform, Cardiff, Vista, CA). After 3
weeks, a reminder was sent. Questionnaires with missing
data or unclear information were completed by telephone
calls. Data from questionnaires were added to the data
retrieved from the medical files. In case the information from
the questionnaires did not correspond with information from
the medical files, information from the medical files was
assumed to be superior. A total of 5,927 questionnaires were
returned, corresponding to a response rate of 61%.
Data on cancer occurrence through linkage with population-
based registers
The occurrence of cancer, as assessed through information in
the medical files and questionnaires, was supplemented by
record linkage to the NCR. The NCR has nation-wide
coverage since 1989. At the time of linkage, cancer incidence
data were complete until 2003. Linkage was performed for all
living and deceased patients, except for those who explicitly
refused (n¼ 406). Although nonresponders and deceased
patients did not give explicit consent, linkage to the NCR is
allowed using a strict privacy procedure (Ronckers, 2001). To
assess cancer occurrence among patients who died before
1989, all deaths were linked to the Causes of Death Registry
of Statistics Netherlands. This registry has been recording
causes of death information in the Netherlands since 1901.
If information retrieved from the NCR did not correspond
with the information in the questionnaires and/or medical files,
the information from the NCR was assumed to be superior.
Statistical analysis
Multivariable proportional hazards regression models were used
to estimate the relative risk of cancer after coal tar treatment.
Follow-up for each patient was calculated as the time from date
of diagnosis of psoriasis or eczema until date of diagnosis of
cancer, date of death, date of loss to follow-up, or 31 December
2003, whichever came first. Separate analyses were conducted
on specific outcomes: (1) overall cancer (total of all the tumors),
(2) skin cancer (excluding basal cell carcinoma), (3) non-skin
cancer, and (4) different (groups of) tumor sites. If a patient was
diagnosed with multiple tumors, only the first tumor was
included in the analyses on overall cancer.
Coal tar exposure was divided into two categories: a
reference/control category (‘‘non-exposure’’ category) of
patients treated with dermatocorticosteroids alone (assumed
to carry no increased risk of cancer) and an exposure category
of patients treated with coal tar (including pix lithantracis and/
or liquor carbonis detergens). As pix lithantracis contains far
more carcinogenic PAHs than liquor carbonis detergens, the
analyses were also performed with coal tar exposure divided
into three categories: reference (similar to above), ‘‘high
exposure’’ including patients treated with pix lithantracis
(regardless of exposure to liquor carbonis detergens), and
‘‘low exposure’’ including patients treated with liquor
carbonis detergens only. Patients in the exposure categories
could also have been treated with other therapies (e.g.,
ointments, photo(chemo)therapy, or systemic therapies).
In all final models, the risk of coal tar was adjusted for age
(continuous), gender, severity of skin disease (410% body area
affected vs o10%), an interaction term of coal tar and severity,
calendar period of diagnosis (1960–1969, 1970–1979, and
1980–1989), PUVA (yes vs no), systemic therapy (yes vs no),
and smoking (current smoking and ever smoked vs never
smoked). We chose the moment at which the skin disease was
most extensive for assessing the maximum severity of the skin
disease. We did not use any information on fluctuations of
severity in the analyses. The models were not adjusted for skin
type, history of sun exposure, or alcohol consumption, because
these variables did not alter the risk estimates of the treatment
effects in the proportional hazards models.
Data on smoking habits were only available from the
patients with a completed questionnaire and were conse-
quently missing in a large proportion of the cohort (58%). To
handle these missing data, a multiple imputation technique
was used (Donders et al., 2006; Moons et al., 2006; van der
Heijden et al., 2006). The proportionality assumption of each
variable was checked by visual inspection of log–log survival
plots and by examining the effect of adding a time-dependent
interaction term. Analyses were performed with SAS version
8.2 (SAS Institute, Cary, NC).
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